Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients

C Wang, K Zhao, S Hu, W Dong, Y Gong, M Li, C Xie - Lung Cancer, 2022 - Elsevier
Background The purpose of this study was to investigate the outcomes of gefitinib and
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …
被引用次数：6 相关文章

Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients

C Wang, K Zhao, S Hu, W Dong… - Lung cancer …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The purpose of this study was to investigate the outcomes of gefitinib and
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …

Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.

C Wang, K Zhao, S Hu, W Dong, Y Gong… - Lung Cancer …, 2022 - europepmc.org
Background The purpose of this study was to investigate the outcomes of gefitinib and
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …
[PDF] google.com

[PDF][PDF] Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients

C Wang, K Zhao, S Hu, W Dong, Y Gong, M Li… - Lung …, 2022 - drive.google.com
Background: The purpose of this study was to investigate the outcomes of gefitinib and
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …

Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients

C Wang, K Zhao, S Hu, W Dong, Y Gong, M Li… - Lung …, 2022 - lungcancerjournal.info
Background The purpose of this study was to investigate the outcomes of gefitinib and
erlotinib in patients with non-small cell lung cancer (NSCLC) with uncommon epidermal …